Stocks · News reference

AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027

Jun 18, 2026, 1:10 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncSep 2, 2026, 12:43 PMNa
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech announced patent protection for Ampligen across 18 European countries and the United Kingdom through June 2041 for Long COVID treatment. The company also recently secured a U.S. patent for Ampligen combined with pembrolizumab for cancer treatment. These patents strengthen AIM's global intellectual property position around its dsRNA immunomodulator platform across multiple therapeutic indications.
AIM
BenzingaAug 31, 2026, 5:35 PMBenzinga Newsdesk
AIM ImmunoTech shares are trading lower. The company announced USPTO has granted a patent covering the use of drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.
AIM
BenzingaAug 31, 2026, 12:52 PMBenzinga Newsdesk
AIM ImmunoTech Announces USPTO Granted Patent Covering Use Of Ampligen In Combination With Pembrolizumab For Cancer Treatment, Expiring December 20, 2039
AIM
BenzingaAug 20, 2026, 10:01 AMBenzinga Newsdesk
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7
AIM